Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for PTN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 -0.0385M
December 31, 2025 -0.0128M
September 30, 2025 0.00
June 30, 2025 0.63M
March 31, 2025 0.00
December 31, 2024 2.50M
September 30, 2024 0.00
June 30, 2024 -0.0049M
March 31, 2024 0.00
December 31, 2023 9.462M
September 30, 2023 2.993M
June 30, 2023 -3.045M
March 31, 2023 -0.1169M
December 31, 2022 -0.1234M
September 30, 2022 -0.1412M
June 30, 2022 -0.0371M
March 31, 2022 -0.0774M
December 31, 2021 -0.0891M
September 30, 2021 -0.0578M
June 30, 2021 0.00
March 31, 2021 -0.0057M
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
March 31, 2020 0.00
Date Value
December 31, 2019 0.00
September 30, 2019 -0.0629M
June 30, 2019 0.00
March 31, 2019 -0.0361M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 -0.013M
March 31, 2018 0.00
December 31, 2017 0.25M
September 30, 2017 -0.0095M
June 30, 2017 0.5416M
March 31, 2017 0.45M
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 -1.387M
September 30, 2015 -0.0177M
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 1.500M
December 31, 2013 2.25M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Decoy Therapeutics, Inc. -0.0424M
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M
Anika Therapeutics, Inc. -1.28M
Savara, Inc. 32.60M